‘Hodgkin’s Lymphoma Day’ Webcast to Discuss Affimed’s Clinical-stage Immunotherapy

‘Hodgkin’s Lymphoma Day’ Webcast to Discuss Affimed’s Clinical-stage Immunotherapy
0
(0)

Affimed N.V. recently announced its planned Hodgkin’s Lymphoma Day live webcast, where company executives will be joined by cancer experts to discuss developments in disease treatment and, particularly, to present Affimed’s leading Hodgkin’s lymphoma immunotherapy candidate, based on NK-cell biology, that is now in clinical testing.

The 3.5-hour webcast will take place in New York City on Jan. 26, 2016,  starting at 10 a.m.

Hodgkin’s lymphoma is a type of lymphoma in which cancer stems from lymphocytes, a sub-type of the immune system’s white blood cells. Two of the strongest cells of the human defense arsenal are a particular set of these white blood cells, called NK-cells (for “natural killer”) and T-cells. Affimed’s proprietary antibodies, TandAbs, are designed to bridge either NK-cells or T-cells and cancer cells, triggering a cancer-eliminating signaling cascade. The specific NK-cell-engaging TandAb, AFM13, will be the focus of this institutional investors’ event.

Jens-Peter Marschner, MD, Affimed’s CMO, and Martin Treder, PhD, company CSO, will moderate the discussion, and be available to talk about AFM13, which is currently in a Phase 2a trial in patients with relapsed or refractory Hodgkin’s  lymphoma.

The four experts, invited to discuss NK-cell biology, immunotherapy and Hodgkin’s lymphoma, are:

  • Holbrook Kohrt, MD, PhD, Stanford University Medical Center in Stanford, California
    • Dr. Kohrt will discuss the rationale for the use of combination therapies in cancer based on his preclinical work with AFM13;
  • Michael Caligiuri, MD, The Ohio State University Comprehensive Cancer Center in Columbus, Ohio
    • Dr. Caligiuri will focus on NK-cells and their modulation by the PD-1/PD-L1 axis;
  • Andrew Evens, DO, MSc, FACP, Tufts Medical Center in Boston, Massachusetts
    • Dr. Evens will address both challenges and opportunities in treatment options for Hodgkin’s lymphoma, including immunotherapies;
  • Andreas Engert, MD, PhD, University Hospital Cologne in Germany
    • Dr. Engert will discuss current knowledge of Hodgkin’s lymphoma, available treatments, and the need for better therapies.

The Hodgkin’s Lymphoma Day webcast  will be available live though the “investors” section of the company’s website and remain active for 30 days after the event.

Affimed, based in Heidelberg, Germany, is a clinical-stage biopharmaceutical company focused on discovering and developing targeted cancer immunotherapies.

Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
×
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
Latest Posts
  • Tafasitamab combo, lymphoma
  • blood biomarkers
  • CTCL
  • CHMP opinion

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Tagged , , , , , , .

Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.